Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer: Plans For Boosters Will Not Divert Supplies From Poorer Nations

Manufacturing Output Could End Vaccine Inequity In 2022

Executive Summary

Pfizer has pledged to supply 41% of its COVID-19 vaccine output to developing nations – but warns that these countries still need to sign contracts on time to guarantee supplies.

You may also be interested in...



US FDA Signals New COVID-19 Vaccines Could Be Authorized With Just Immunogenicity Studies

As FDA lowers some expectations on timing of booster shots, agencys outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.

Cellino Raises $80m Series A To Transform Stem Cell Therapy Manufacturing

The Cambridge, MA start-up aims to ‘democratize’ therapies based on induced pluripotent stem cells by developing an automated manufacturing system.

Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer

While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel